3.0
Feb 5, 2017
Current employee, less than 1 year
Cambridge, England
Recommend
CEO approval
Business outlook
Pros
Great product and opportunity to help prevent morbidity and mortality of patients with CV disease. Company infrastructure us improving but a long way to go. Need better focus.
Cons
Politics getting in the way of launch plans. Company hires people with expertise, and then Senior Managers who have no experience in the disease area but have longevity start to interfere and try and control the approach in the wrong way.